PureTech affiliate Alivio granted two key US patents

Clinical-stage biopharmaceutical company PureTech Health announced on Tuesday that its affiliate Alivio Therapeutics has been granted two key patents broadly covering its inflammation-targeting technology platform.

The London-listed firm said Alivio's newest patents issued by the United States Patent and Trademark Office - numbers 9,962,339 and 9,974,859 - broadly covered compositions of matter and other aspects of the inflammation-targeting microfibre materials with embedded molecules of interest.

It said the patents lay a “strong foundation” for Alivio to expand its intellectual property portfolio for the unique technology platform.

Both patents were exclusively licensed by Alivio from Brigham and Women's Hospital and the Massachusetts Institute of Technology.

“PureTech's mission is to pioneer new categories of medicine that address serious chronic diseases in a highly targeted manner,” said PureTech chief of research and strategy Eric Elenko.

“One area of focus for us is autoimmune disease, such as inflammatory bowel disease and other inflammatory conditions, and Alivio is pioneering inflammation-targeting technology to offer safe and effective treatment options for patients living with these challenging disorders.

“These new patents validate the uniqueness of Alivio's approach and are foundational to this affiliate's growing pipeline of targeted immunomodulation opportunities.£

PureTech noted that in April, a preclinical study of Alivio's technology platform was published in Nature Communications, demonstrating proof-of-concept that an immunomodulatory drug - administered locally using the Alivio inflammation-targeting technology - substantially reduced measures of arthritis disease activity, with a 5.7-fold improvement in the disease clinical score versus control, as compared to only 1.4-fold for the free drug.

In July last year, Alivio presented data for product candidate ALV-107, showing durable pain control throughout a 24-hour study period, lasting at least 12 times longer than lidocaine at a comparable dose, in a validated preclinical model for the treatment of interstitial cystitis/bladder pain syndrome.